89Zr-girentuximab PET/CT 可辅助诊断透明细胞肾细胞癌的疑难病例
基于碳酸酐酶IX(CAIX)在95%透明细胞肾细胞癌(ccRCC)中高表达,本研究探索89Zr标记的girentuximab PET/CT在ccRCC诊断困境中的价值。对原发肾脏肿块(n=16)或ccRCC病史(n=14)患者注射89Zr-girentuximab后4或5天行PET/CT,结果显示所有切除的PET阳性原发灶均为ccRCC,PET阴性肿块未见进展;在疑似复发/转移患者中,该检查有助于确认或排除ccRCC、评估病变范围及与其他癌症鉴别,并使5例(36%)患者临床管理发生重大改变,3例(21%)避免重复活检。结论认为89Zr-girentuximab PET/CT是指导ccRCC诊断困境临床决策的有价值工具。
要点
- 所有切除的PET阳性原发灶均为ccRCC,PET阴性肿块未见进展。
- 疑似复发/转移患者中,5例(36%)临床管理重大改变,3例(21%)避免重复活检。
- 89Zr-girentuximab PET/CT可辅助ccRCC诊断困境的临床决策。
核心结论
- 89Zr-girentuximab PET/CT是指导ccRCC诊断困境临床决策的有价值诊断工具。
研究设计与样本
- 临床研究,原发肾脏肿块患者16例和ccRCC病史患者14例,注射89Zr-girentuximab后4或5天行PET/CT。
主要发现
- 所有切除的PET阳性原发病灶均为ccRCC,PET阴性肿块未见病变进展。
- 疑似复发/转移患者中,该检查有助于确认或排除ccRCC、评估病变范围及与其他癌症鉴别。
- 该组中5例(36%)临床管理发生重大改变,3例(21%)避免重复活检。
关键数值与推荐
- CAIX在95%的ccRCC中高表达,girentuximab为抗CAIX单克隆抗体。
- PET/CT于注射89Zr-girentuximab后4或5天进行。
- 原发肾脏肿块患者16例,ccRCC病史患者14例。
- 疑似复发/转移组中5例(36%)管理重大改变,3例(21%)避免重复活检。
临床怎么用
- 对于诊断不明确的肾脏肿块,89Zr-girentuximab PET/CT可用于辅助手术或主动监测的决策。
- 对于疑似复发/转移的ccRCC患者,该检查有助于确认或排除ccRCC、评估病变范围及鉴别其他癌症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Based on the high expression of carbonic anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study explores the value of 89Zr-labeled girentuximab positron emission tomography/computed tomography (PET/CT) imaging in diagnostic challenges regarding ccRCC. PET/CT imaging was performed 4 or 5 d after injection of 89Zr-girentuximab in patients with a primary renal mass (n=16) or a history of ccRCC (n=14). Scans were used for decision making (surgery/active surveillance) in case of indistinct renal masses. All resected PET-positive primary lesions proved to be ccRCC, while no lesion progression was seen in PET-negative masses. In patients suspected of recurrent/metastatic ccRCC, PET/CT with 89Zr-girentuximab was useful to confirm or exclude ccRCC, evaluate the extent of the disease, and differentiate from other cancers. In this group, 89Zr-girentuximab PET/CT resulted in a major change in clinical management in five patients (36%), while in three patients (21%) repeat biopsies could be avoided. We conclude that 89Zr-girentuximab PET/CT is a valuable diagnostic tool that can guide clinical decision making in case of diagnostic dilemmas concerning ccRCC suspicion. PATIENT SUMMARY: Positron emission tomography/computed tomography imaging with 89Zr-girentuximab can be a valuable diagnostic tool to identify clear cell renal cell carcinoma.
引用
- Hekman MCH, Rijpkema M, Aarntzen EH, et al. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. Eur Urol. 2018. PMID: 29730017. doi:10.1016/j.eururo.2018.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。